The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-16. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
On 21 March 2020, Bukele imposed a 30-day nationwide lockdown in an effort to combat the pandemic. During the lockdown, 4,236 people were arrested by the National Civil Police for violating the lockdown order; 70 were arrested before the lockdown order became public. The arrestees were quarantined in a "containment center". Human rights organizations such as Human Rights Watch criticized the arrests, citing instances of arbitrary arrests and abuse by police. Amid April 2020 lockdowns in the country's prisons and published images of prisoners lined up in cramped positions, Human Rights Watch called the prisons' living conditions "inhumane" (particularly in light of the pandemic). On 27 May 2020, the United States donated 250 ventilators to El Salvador. During a press conference where Bukele received the ventilators, he said that he took hydroxychloroquine as prophylaxis and added that "most of the world's leaders use [hydroxychloroquine] as a prophylaxis". Bukele inaugurated the Hospital El Salvador, the largest hospital in Latin America used exclusively for treating cases of COVID-19 at the site of the former International Center for Fairs and Conventions, on 22 June 2020. The hospital had a capacity of 400 beds, 105 intensive-care units, and 295 intermediate-care units staffed by 240 doctors. In August 2020, the hospital's capacity was increased by 575 beds. It began treating conditions other than COVID-19 by June 2022.
The IDF also said that it killed two Lebanese militants attempting to infiltrate the border and plant an explosive at an IDF post. Two Israeli soldiers were killed and nine others were injured in Hezbollah attacks in the vicinity of the Lebanese border. Three rockets launched by Hezbollah to Metula caused fires and damaged electric infrastructure. The IDF said that its jets struck more than a hundred Hezbollah rocket launchers and other Hezbollah sites in its heaviest air strikes since the Israel–Hezbollah conflict started in October 2023. An Israeli strike in al-Haniyeh wounded four people. The Lebanese National News Agency reported that Israeli airstrikes targeted Mahmoudieh, Ksar al-Aroush, and Birket Jabbour. On 20 September, an Israeli strike in the Dahieh suburb of Beirut killed Ibrahim Aqil, the acting commander of the elite Redwan Force and other personnel including Ahmad Mahmoud Wahabi, a senior commander of Hezbollah while they were in a meeting. At least 45 people were killed including Aqil, Wahabi, another 14 high-ranking Hezbollah militants, three children, and seven women, while 68 people were injured. Heavy rocket fire was reported afterward in northern Israel. Hezbollah claimed that its Katyusha rockets struck the IDF base in Meron. Hezbollah also said that it targeted Israeli airbases, intelligence bases, and a tank. On 21 September, the IDF claimed to have "almost completely dismantled" Hezbollah's military chain of command. The IDF claimed that it destroyed thousands of rocket launchers. Four people were wounded in Israeli strikes.
Y-90, used for treating lymphoma (2.7 days) I-131, used for thyroid function tests and for treating thyroid cancer (8.0 days) Sr-89, used for treating bone cancer, intravenous injection (52 days) Ir-192, used for brachytherapy (74 days) Co-60, used for brachytherapy and external radiotherapy (5.3 years) Cs-137, used for brachytherapy and external radiotherapy (30 years) Tc-99, product of the decay of technetium-99m (221,000 years)
== Clinical implications == The MEN1 phenotype is inherited via an autosomal-dominant pattern and is associated with neoplasms of the pituitary gland, the parathyroid gland, and the pancreas (the 3 "P"s). While these neoplasias are often benign (in contrast to tumours occurring in MEN2A), they are adenomas and, therefore, produce endocrine phenotypes. Pancreatic presentations of the MEN1 phenotype may manifest as Zollinger–Ellison syndrome. MEN1 pituitary tumours are adenomas of anterior cells, typically prolactinomas or growth hormone-secreting. Pancreatic tumours involve the islet cells, giving rise to gastrinomas or insulinomas. In rare cases, adrenal cortex tumours are also seen.
== Campaign == The campaign for was unusually short, lasting only seven weeks after the vote was brought forward from May to 18 March following negotiations between the Round Table and the government of Hans Modrow on 28 January. This tight schedule posed significant organizational challenges. Only the PDS, as the successor to the SED, possessed the necessary infrastructure and financial resources for a full campaign. In contrast, newly formed opposition parties and civil rights groups were still defining their platforms and had minimal experience in electioneering. Their shortcomings were partially mitigated by substantial support from West German parties, which provided logistical and strategic assistance to their Eastern counterparts. Western support facilitated the creation of several electoral alliances. The CDU partnered with the German Social Union and Democratic Awakening to form the Alliance for Germany. The FDP backed the Association of Free Democrats, which included the Liberal Democratic Party of Germany (LDPD) and the minor FDP of the GDR. These alliances were established only weeks before the election, relying heavily on Western assistance such as the CDU's "district partnerships" and the participation of West German campaigners. At the outset, the SPD appeared likely to win, benefiting from historical roots in the region and strong backing from the West German SPD. Early polls showed it leading with 54 percent support, ahead of the PDS and CDU. Despite early advantages, the SPD's momentum declined as reunification became the dominant issue.
Sources: en.wikipedia.org
Several of the CPK colors refer mnemonically to colors of the pure elements or notable compound. For example, hydrogen is a colorless gas, carbon as charcoal, graphite or coke is black, sulfur powder is yellow, chlorine is a greenish gas, bromine is a dark red liquid, iodine in ether is violet, amorphous phosphorus is red, rust is dark orange-red, etc. For some colors, such as those of oxygen and nitrogen, the inspiration is less clear. Perhaps red for oxygen is inspired by the fact that oxygen is normally required for combustion or that the oxygen-bearing chemical in blood, hemoglobin, is bright red, and the blue for nitrogen by the fact that nitrogen is the main component of Earth's atmosphere, which appears to human eyes as being colored sky blue. It is likely that the CPK colours were inspired by models in the nineteenth century. In 1865, August Wilhelm von Hofmann, in a talk at the Royal Institution in London, was using models made from croquet balls to illustrate valence, so he used the coloured balls available to him. (At the time, croquet was the most popular sport in England, so the balls were plentiful.) The essay "On the Combining Power of Atoms", in the 12th volume of Chemical News, states that "Hofmann, at a lecture given at the Royal Institution in April 1865 made use of croquet balls of different colours to represent various kinds of atoms (e.g. carbon black, hydrogen white, chlorine green, 'fiery' oxygen red, nitrogen blue)."
Moscow is situated on the banks of the Moskva River, which flows for about 500 kilometers (310 mi) through the East European Plain in Central Russia, not far from the natural border of the forest and the forest-steppe zone. A total of 49 bridges span the river and its canals within city limits. Moscow's elevation at the All-Russia Exhibition Center (VVC)—where the leading Moscow weather station is located—is 156 meters (512 ft). Teplostan Upland is the city's highest point at 255 meters (837 ft). The width of the city (excluding the MKAD) from west to east is 39.7 kilometers (24.7 mi), and the length from north to south is 51.8 kilometers (32.2 mi).
The production of pure alkali metals is somewhat complicated due to their extreme reactivity with commonly used substances, such as water. From their silicate ores, all the stable alkali metals may be obtained the same way: sulfuric acid is first used to dissolve the desired alkali metal ion and aluminium(III) ions from the ore (leaching), whereupon basic precipitation removes aluminium ions from the mixture by precipitating it as the hydroxide. The remaining insoluble alkali metal carbonate is then precipitated selectively; the salt is then dissolved in hydrochloric acid to produce the chloride. The result is then left to evaporate and the alkali metal can then be isolated. Lithium and sodium are typically isolated through electrolysis from their liquid chlorides, with calcium chloride typically added to lower the melting point of the mixture. The heavier alkali metals, however, are more typically isolated in a different way, where a reducing agent (typically sodium for potassium and magnesium or calcium for the heaviest alkali metals) is used to reduce the alkali metal chloride. The liquid or gaseous product (the alkali metal) then undergoes fractional distillation for purification. Most routes to the pure alkali metals require the use of electrolysis due to their high reactivity; one of the few which does not is the pyrolysis of the corresponding alkali metal azide, which yields the metal for sodium, potassium, rubidium, and caesium and the nitride for lithium. Lithium salts have to be extracted from the water of mineral springs, brine pools, and brine deposits.
=== Diaphragm check valve === A diaphragm check valve uses a flexing rubber diaphragm positioned to create a normally-closed valve. Pressure on the upstream side must be greater than the pressure on the downstream side by a certain amount, known as the pressure differential, for the check valve to open allowing flow. Once positive pressure stops, the diaphragm automatically flexes back to its original closed position. This type is used in respirators (face masks) with an exhalation valve.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.